New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved

Core Insights - Medtronic has received FDA approval for the Simplera Sync™ sensor, enhancing the MiniMed™ 780G system's capabilities in the U.S. market [1][3] - The Simplera Sync™ sensor is a disposable, all-in-one device that eliminates the need for fingersticks and simplifies the insertion process, providing greater flexibility for users [2][6] - The MiniMed™ 780G system features an adaptive algorithm that adjusts glucose levels every 5 minutes, utilizing Meal Detection™ technology to optimize insulin delivery [2][3] Product Features - The Simplera Sync™ sensor is designed to work seamlessly with the MiniMed™ 780G system, which can now utilize both the Guardian™ 4 sensor and the new Simplera Sync™ sensor [1][3] - The system allows for flexible glucose targets as low as 100 mg/dL and has shown real-world data indicating users achieve over 70% time in range when using optimal settings [2][6] - The MiniMed™ 780G system is the only one that can be paired with an infusion set lasting up to 7 days, significantly reducing the frequency of injections [2][6] Company Commitment - Medtronic is dedicated to innovating diabetes management technologies to improve the quality of life for individuals living with diabetes [3][4] - The company plans a limited launch of the Simplera Sync™ sensor in the U.S. in fall 2025, further expanding its CGM options [3][4] - Medtronic has a long history of pioneering diabetes technology and aims to continue leading in this field through advanced sensors and intelligent dosing systems [4][5]